ClinicalTrials.gg
RecruitingNCT06620523Updated Oct 14, 2026

Prevent Cardiac Surgery Associated AKI Trial

A Phase 2 interventional study of CoQ10 1200 mg orally with Glutathione 1000 mg orally and Group B: Placebo CoQ10 orally and Placebo Glutathione orally in Renal Failure, Coronary Artery Disease and Surgery, sponsored by George Washington University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by George Washington University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 554 studies in Renal Insufficiency with a site in United States — 41 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Planned enrollment
51st of 469
242 · median 32
Started
2024
with 19 others
Phase 2
48 of 554
5 open now
Primary completion
2027-06
later than 30 of 56 live
Registered
511th of 554
by date

Among the 554 studies in Renal Insufficiency with a site in United States, this one is the 51st largest by planned enrollment of the 469 interventional ones that give a count, is one of 20 that started in 2024, is one of 48 in phase 2, reaches primary completion later than 30 of the 56 other live ones, and was the 511th registered.

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

41 of the 554 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Renal Insufficiency studies recruiting now, 49 (52%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 554 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.

Read the detailed description

AKI (Acute Kidney Injury) is a serious and common complication post Cardiac surgery requiring cardiopulmonary bypass (CPB), the incidence is up to 30% Independent predictor for 30-day mortality, with a 41 % \& % 62% in AKI stage III without and with the needs for RRT (Renal Replacement Therapy) respectively It's also associated with an a 3-fold increase in the long-term risk of ESRD (End Stage Renal Disease) Despite the high burden of CPB-induced AKI, our understanding of the pathophysiology still primitive, that makes us limited in designing directed therapies for prophylaxis, early detection and interventions that can lower its incidence, severity and progression. CPB induced AKI is multifactorial, however, renal ischemia-reperfusion injury (RIRI) is considered a major factor, poor renal perfusion driven by hemodynamic and volume changes, increased systemic inflammation, endothelial and epithelial cell injury and perioperative use of nephrotoxic agents all contribute to AKI post cardiac surgery.

Renal mitochondrial dysfunction has been implicated in the pathogenesis of RIRI, reperfusion following ischemia causes opening of mitochondrial permeability transition pore (MPTP), leading to depolarization of mitochondrial membrane, increased production of reactive oxygen species (ROS) and release of apoptotic proteins mitochondrial disruption contributes to impairment of ATP dependent cellular repair mechanisms, cell death, and persistent suppression of mitochondrial biogenesis, a process of which cells form new mitochondria furthermore, cell injury releases mitochondrial endogenous damage associated molecular patterns (DAMPs), Mitochondrial DAMPs (MTD) activates toll-like receptor-9 (TLR9) which results in innate immune cascade activation and further renal injury Loss of Mitochondrial function and integrity has been linked to initiation, progression and recovery phases of ischemia/ reperfusion acute kidney injury. In mice subjected to Sham surgery, UmtDNA (Urinary Mitochondrial Deoxyribonucleic Acid) increased after 10 min of ischemia, positively correlated with ischemia time and negatively correlated with renal cortical mtDNA and mitochondrial gene expression Levels of UmtDNA in AKI was evaluated with different population and different results. UmtDNA level correlated with renal function recovery but not with AKI severity following cardiac surgery. Same finding of correlation between UmtDNA with renal recovery was observed but wasn't statistically significant, additionally UmtDNA level reflected the severity of AKI and duration of renal replacement therapy in patients admitted with AKI Co Q10 or ubiquinone is an essential mitochondrial co-factor that has a critical role as a component of the electron transport chain and free radical scavenger. Co Q10 levels were found to be low in critically ill patients, lower levels found in post cardiac arrest with correlation poor neurological outcome and higher mortality. American heart association included CoQ10 as a promising neuroprotective agent, significantly lower left ventricular ejection fractions (LVEFs) seen in the lowest tertile of CoQ10 Biopsies taken from patients with cardiomyopathy showing increasing severity of heart disease correlate with lower levels of serum and myocardial deficiency of CoQ10, supplementation with CoQ10 resulted in significant increases in both myocardial and serum levels as well as reduction of disease severity. Coenzyme Q10 as Adjunctive Treatment of Chronic Heart Failure has shown that CoQ10 supplement reduced the primary 2-year end point of cardiovascular death, hospital stays for HF (Heart Failure), or mechanical support or cardiac transplant. It was also demonstrated that CoQ10 reduced the risk of congestive heart failure hospitalization and its complications like pulmonary edema and cardiac asthma Q12 supplement is safe and widely available as an over-the-counter, CoQ10 is available as ubiquinol (reduced form) or ubiquinone (oxidized form), Additionally, the ubiquinol containing formulation resulted in a higher plasma CoQ10 levels compared with ubiquinone formulations after a single dose of supplement. Dose of 1200 mg chose based on safety shown in many clinical trial data for CoQ10. The half-life of CoQ10 is 21.7 h (28 Mitochondria consume about 90% of the cellular O2 for ATP (Adenosine Tri-Phosphate) synthesis through oxidative phosphorylation, optimizing mitochondrial function and reducing oxygen free radicals may enhance cellular function and mitigate cellular injury thereby leading to improved outcome. Despite the accumulating evidence on the relevance of mitochondrial dysfunction in AKI initiation and progression and the crucial role mitochondrial therapies such as Co Q10 \& Glutathione would play in renal protection and recovery, human data in this field are very limited. Using renal scintigraphy \& immunohistochemical evaluation, it was demonstrated that CoQ10 decreased tissue oxidative stress levels, scores of histopathology and apoptosis; and decreased quantitative scintigraphic parameters with increased split renal function in ischemic kidney. The mitochondria-targeted Triphenylphosphine CoQ10 nanoparticles (T-NPCoQ10) which resulted in alleviation of mtDNA damage, suppressed inflammatory and apoptotic responses, and improved renal function in both cell and animal models. In human Co Q10 with Trimetazidine significantly lowered the incidence of Contrast induced nephropathy in previous research.

Glutathione (GSH): In addition to Oxidative stress as a key in cardiac surgery associated AKI; iron-dependent lipid peroxidation resulting in cell death play an important role, this process starts with intracellular glutathione (GSH) depletion. Glutathione S-transferases (GST) are a diverse group of phase II detoxification enzymes that works as a scavenger through conjugation of glutathione to a wide variety of electrophiles and reactive oxygen species. Alpha-GST isoform(a-GST) has specificity for the proximal tubule, and pi- GST isoform(pi-GST) that's confined to distal tubule.

It was demonstrated that post cardiac surgery Urinary pi- GST levels predicted development of AKI and overall prognosis in ischemia/reperfusion mouse models that total GST activity is reduced by \~35% during (0 4 h) AKI "initiation" and (18 or 72 h) "maintenance" phases. In previous research, acute kidney injury model established by systemic glutathione depletion in mice. In patients undergoing cardiac surgery, low levels of cardiac and systemic glutathione found to correlate to the functional status and structural cardiac abnormalities of patients with cardiac diseases it was shown that that high levels of serum GST Pi in the first 6 h after birth are associated with an increased AKI and mortality in prematurely born neonates. Experiment showed exogenous glutathione supplement alleviated Gentamicin induced AKI in rats intoxicated with gentamycin, partially by inhibiting oxidative stress, and intrinsic apoptosis. Glutathione supplements are safe and already available over the counter, studies have shown effectiveness of daily Glutathione administration at elevating stores of Glutathione and impacting the immune function and levels of oxidative stress

03

Conditions studied

  • Renal Failure
  • Coronary Artery Disease
  • Surgery
  • Surgery-Complications

Keywords

  • cardiac surgery
  • critical care medicine
  • anesthesiology
  • nephrology
  • cardiopulmonary bypass
  • renal failure
  • aki
  • supplement
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult 18-70 years of age
  • Undergoing elective CPB (Cardiopulmonary Bypass) surgery
  • Baseline (Glomerular Filtration Rate) ≥45 ml/min

Exclusion criteria

Exclusion Criteria:

  • (Glomerular Filtration Rate) \<45 ml/min
  • Solitary kidney
  • Status post-kidney transplant
  • Pregnant women
  • Allergy to CoQ10
  • Allergy to Glutathione
  • Allergy to Cellulose
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
242 participants (estimated)

Study arms

  • Active comparator
    Group A: CoQ10 1200 mg orally with Glutathione 1000 mg orally

    White-colored CoQ10 400 mg capsules will be dispensed AND White colored L-Glutathione 500 mg capsules will be dispensed.

    Drug: CoQ10 1200 mg orally with Glutathione 1000 mg orally

  • Placebo comparator
    Group B: Placebo CoQ10 orally and Placebo Glutathione orally

    A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.

    Drug: Group B: Placebo CoQ10 orally and Placebo Glutathione orally

Interventions

  • DrugCoQ10 1200 mg orally with Glutathione 1000 mg orally

    Drug page: Coenzyme Q10Studies of Coenzyme Q10Coenzyme Q10 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury

  • DrugGroup B: Placebo CoQ10 orally and Placebo Glutathione orally

    A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.

06

What researchers measure

Primary outcomes

  1. AKI incidence reduction

    Reduction of cardiac surgery associated acute kidney injury

    Time frame: 28 days

  2. AKI incidence reduction

    Reduction of cardiac surgery associated acute kidney injury

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.

Of 26 phase 2 interventional studies under Renal Insufficiency, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 34. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Oct 1, 2024
StartActual
Jul 18, 2024
Primary completionEst.
Jun 17, 2027
CompletionEst.
Jun 17, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06620523
Responsible party
yoosif abdalla (Principal Investigator, George Washington University) — Principal investigator
First posted
Oct 1, 2024
Start date
Jul 18, 2024
Primary completion
Jun 17, 2027 (estimated)
Completion
Jun 17, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Eduard Shaykhinurov, MS
Contact
eshaykhinurov@mfa.gwu.edu
2028234259
Yoosif Abdalla, MD
Contact
Yoosif Abdalla, MD
principal investigator · George Washington University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Coenzyme Q10

Start the discussion